

Zhen Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5052851/publications.pdf>

Version: 2024-02-01

20
papers

209
citations

1040056

9
h-index

1125743

13
g-index

21
all docs

21
docs citations

21
times ranked

338
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	30
2	Iridubin-3-oxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. <i>EBioMedicine</i> , 2022, 78, 103950.	6.1	15
3	Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant. <i>Annals of Hematology</i> , 2022, 101, 1201-1210.	1.8	1
4	Four and a Half LIM Domains Protein 2 Mediates Bortezomib-Induced Osteogenic Differentiation of Mesenchymal Stem Cells in Multiple Myeloma Through p53 Signaling and β -Catenin Nuclear Enrichment. <i>Frontiers in Oncology</i> , 2021, 11, 729799.	2.8	3
5	Clonal Heterogeneity and Evolutionary Phylogeny of Critical Cytogenetic Aberrations in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1608-1608.	1.4	1
6	Raman spectroscopy-based biomarker screening by studying the fingerprint characteristics of chronic lymphocytic leukemia and diffuse large B-cell lymphoma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 190, 113514.	2.8	20
7	TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia. <i>Chinese Medical Journal</i> , 2020, 133, 2090-2097.	2.3	1
8	Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment. <i>Scientific Reports</i> , 2020, 10, 20508.	3.3	22
9	Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e652-e659.	0.4	7
10	Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma. <i>Cancer Gene Therapy</i> , 2020, 27, 869-877.	4.6	11
11	Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. <i>Molecular Cancer Research</i> , 2020, 18, 1063-1073.	3.4	22
12	Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders. <i>Oncotarget</i> , 2018, 9, 3353-3364.	1.8	5
13	The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study. <i>International Journal of Hematology</i> , 2017, 106, 418-425.	1.6	8
14	BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase. <i>BMC Medical Genetics</i> , 2017, 18, 16.	2.1	13
15	Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. <i>Genetics in Medicine</i> , 2017, 19, 182-191.	2.4	17
16	Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2017, 29, 156-165.	2.2	8
17	Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region. <i>Oncotarget</i> , 2017, 8, 98757-98770.	1.8	14
18	Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia. <i>Chinese Medical Journal</i> , 2017, 130, 135-142.	2.3	6

#	ARTICLE	IF	CITATIONS
19	Gene Mutation Signature and Its Pathogenesis Role in Chronic Lymphocytic Leukemia in China: Different from the Western Reports. <i>Blood</i> , 2016, 128, 4360-4360.	1.4	0
20	Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. <i>BMC Cancer</i> , 2015, 15, 555.	2.6	5